Welcome to our dedicated page for Exicure news (Ticker: XCUR), a resource for investors and traders seeking the latest updates and insights on Exicure stock.
Exicure, Inc., formerly known as Aurasense Therapeutics, is a pioneering biotechnology company that is redefining the landscape of immunomodulatory and gene silencing drugs. Leveraging its proprietary 3-dimensional Spherical Nucleic Acid (SNA™) architecture, Exicure is unlocking the therapeutic potential of nucleic acids across multiple organs. The company focuses on developing treatments targeting validated pathways for conditions ranging from inflammatory disorders to oncology.
Exicure's innovative SNA constructs are designed to overcome one of the most significant challenges in nucleic acid therapeutics: the efficient and safe delivery of therapeutic agents into cells and tissues. These constructs offer unparalleled transfection efficiency into various cell and tissue types, including skin, without the need for carriers or transfection agents. Additionally, SNA constructs hold promise as potent immunotherapeutic agents for addressing cancer and infectious diseases.
At the forefront of Exicure's pipeline are treatments for neurological disorders and hair loss, targeting ribonucleic acid (RNA) against validated disease targets. The company operates in a single segment focused on the discovery, research, and development of SNA-based treatments.
Recent milestones for Exicure include advancements in its lead programs, successful preclinical results, and strategic partnerships aimed at accelerating the development and commercialization of its groundbreaking therapies. These achievements underscore the company's commitment to transforming the future of medicine through cutting-edge nucleic acid technology.
The latest news and updates about Exicure, Inc. highlight the company's ongoing progress and significant developments in the biotechnology sector, providing valuable insights for investors and stakeholders.
Exicure, Inc. (NASDAQ: XCUR) has announced significant management changes. Brian C. Bock will resign as President and CEO, transitioning to a Special Advisor role effective immediately. Dr. Matthias Schroff, previously Chief Scientific Officer, will take over as President and CEO on February 4, 2022. Additionally, several Board members, including Timothy P. Walbert and Andrew Sassine, are resigning. Dr. Betsy Garofalo is appointed as Chair of the Board. These changes aim to streamline leadership and enhance operational efficiency in advancing Exicure's gene therapy programs.
Exicure, Inc. (NASDAQ:XCUR) has announced a definitive agreement with institutional investors for a registered direct offering of 34,576,068 shares of common stock at $0.3326 each, plus warrants to purchase another 17,288,034 shares at an exercise price of $0.2701. The expected gross proceeds are about $11.5 million, intended for working capital and corporate purposes. The offering is set to close around December 16, 2021, subject to customary conditions. H.C. Wainwright serves as the exclusive placement agent.
Exicure (NASDAQ: XCUR) announced a 50% workforce reduction and the wind-down of its cavrotolimod and XCUR-FXN programs. The Audit Committee's investigation revealed that former employee Grant Corbett misreported data related to these programs from 2020 to 2021. The company will focus on preclinical programs targeting SCN9A for pain and partnered projects with Ipsen and AbbVie, estimating $6 million in 2022 cost savings and incurring $1.2 million in restructuring expenses.
Exicure, Inc. (NASDAQ: XCUR) reported Q3 2021 results, revealing a net loss of $23.5 million, up from $8.8 million in Q3 2020. R&D expenses surged to $16.5 million, reflecting increased headcount from 48 to 65. Cash reserves rose to $62 million from $57.3 million. Despite a strategic partnership with Ipsen yielding $20 million upfront, the company faces uncertainty due to an ongoing investigation into alleged improprieties related to its XCUR-FXN program. The Phase 1b/2 trial of cavrotolimod is enrolling patients, but results are postponed to H2 2022 due to COVID-19 delays.
Exicure, Inc. (NASDAQ: XCUR) has filed a Form 12b-25 with the SEC, delaying its Q3 2021 10-Q Report due to an ongoing internal investigation prompted by claims of impropriety from a former senior researcher regarding the XCUR-FXN program for Friedreich’s ataxia. The Audit Committee has engaged external counsel for the investigation, and the company is unable to predict its duration or outcome. Exicure aims to submit the 10-Q within five days after the original due date. The firm develops therapies using its proprietary SNA technology for various medical conditions, including neurological disorders.
Exicure, a biotechnology company focused on gene therapy, announced its participation in two significant scientific conferences in November 2021. At TIDES EU, Bart Anderson will present on the development of Spherical Nucleic Acids targeting SCN9A for neuropathic pain on November 16. Additionally, at Neuroscience 2021, presentations will include research on Spherical Nucleic Acids targeting frataxin in Friedreich’s ataxia and their biodistribution in mouse models. Exicure is advancing its therapeutic candidates, including XCUR-FXN for Friedreich’s ataxia and cavrotolimod for advanced solid tumors.
Exicure, Inc. (NASDAQ: XCUR), a biotechnology company specializing in gene regulatory and immunotherapeutic drugs, has announced its participation in two scientific conferences this October. The 17th International Congress on Neuronal Ceroid Lipofuscinosis will feature a presentation on Spherical Nucleic Acids targeting CLN3 for Batten Disease by Grant Corbett on October 8, 2021. Additionally, the International Oligonucleotides and Peptides Conference will see Matthias Schroff discussing their technology on October 18, 2021. Exicure focuses on innovative treatments for various neurological and genetic disorders.
Exicure (NASDAQ: XCUR), a leader in gene regulatory drugs, will present at the Chardan Virtual 5th Annual Genetic Medicines Conference on October 5, 2021, from 11:00 AM to 11:25 AM ET. Attendees can access the presentation via a live webcast. The session will also be available for replay for 30 days afterward. Exicure is focused on therapeutics for various diseases, including Friedreich’s ataxia and advanced solid tumors, leveraging its proprietary Spherical Nucleic Acid technology.
Exicure, Inc. (NASDAQ: XCUR), a biotechnology company focused on gene regulatory and immunotherapeutic innovations, announced that CEO David Giljohann will present at the Benzinga Healthcare Small Cap Conference on September 30, 2021, at 3:20 PM ET. Attendees can register for a free spectator pass and access the live stream here. Exicure is advancing SNA technology for treating various neurological and genetic disorders.
Exicure, Inc. (NASDAQ: XCUR), a leader in gene regulatory and immunotherapeutic drugs, has announced its participation in two scientific conferences in September 2021. These events include TIDES USA 2021, where Exicure will present research on the biodistribution of Spherical Nucleic Acids (SNA) in rats, and the 17th Annual Meeting of the Oligonucleotide Therapeutics Society, focusing on SNA targeting FXN for treating Friedreich's Ataxia. Posters will be available on Exicure's website after the events.
Exicure is based in Chicago and Cambridge, developing therapeutics for various genetic disorders.
FAQ
What is the current stock price of Exicure (XCUR)?
What is the market cap of Exicure (XCUR)?
What does Exicure, Inc. specialize in?
What are the key areas of focus for Exicure's treatments?
What makes Exicure's SNA constructs unique?
What are some recent achievements of Exicure, Inc.?
How does Exicure contribute to cancer and infectious disease treatment?
What is the primary technology used by Exicure, Inc.?
What segment does Exicure operate in?
How does Exicure ensure the safe delivery of nucleic acid therapeutics?
What are the target diseases for Exicure's lead programs?
Where can I find the latest news about Exicure, Inc.?
